Home » Newsletters » BioWorld Science

BioWorld Science

June 12, 2009

View Archived Issues

Lentivirus-based gene transfer may be a promising new therapy for AIDS lymphoma

Pfizer presents vanilloid VR1 receptor ligands for the treatment of pain

Boehringer Ingelheim describes 11beta-HSD inhibitors as antiobesity agents

ND-07 shows preclinical promise in the prevention and treatment of pancreatitis

BioSeek and Merck KGaA enter 3-year collaboration for BioMAP in compound profiling

PharmaMar grants license to Medimetriks for kahalalide F

Takeda claims novel Polo-like kinase inhibitors for cancer treatment

Janssen discovers equilibrate nucleoside transporter 1 inhibitors for the treatment of pain

Statins may reduce levodopa-induced dyskinesia

Studies support extended-release pramipexole in early and advanced Parkinson's disease

Synthetic GPR43 agonist, ESN-282, increases glucose uptake and inhibits lipolysis in vitro

CHMP adopts positive opinion for Otsuka's Samsca in hyponatremia

NorLevo emergency contraceptive pill launched in Canada

ASCO awards 3-year grant for pilot study of bavituximab in advanced NSCLC

Bone Medical submits IND to the FDA for Capsitonin in osteoporosis

Roche and Genentech claim phosphatidylinositol 3-kinase inhibitors as oncolytics

Gene delivery of p53 via the SGT-53 nanocomplex currently evaluated in phase I trial in solid tumors

Glucokinase activator MK-0599 lowers blood glucose in normoglycemic subjects in phase I trial

Biothera initiates Imprime PGG trial in KRAS-mutated colorectal cancer

AEB-071 in combination with tacrolimus shows beneficial effects in renal transplant recipients

FDA Advisory Committee votes favorably on Seroquel supplemental NDAs

Medivation completes enrollment in pivotal phase III CONNECTION trial

Metabasis and Merck & Co. select lead AMPK activator for late preclinical development

Via meets with the FDA to discuss next steps for VIA-2291

Sanofi-aventis and Regeneron report results from aflibercept trial in ovarian cancer patients

FDA Advisory Committee votes in favor of Zyprexa for adolescent indications